interações

Acompanhamento farmacoterapêutico em pacientes com doença renal crônica

Resumo: Background: Health professionals, in recent decades, have directed greater attention to chronic diseases, since these diseases are responsible for a significant portion of the morbidity of the world population, affecting from young people to the elderly. Currently, the main treatments available for end-stage renal disease are: automated peritoneal dialysis, hemodialysis, continuous ambulatory peritoneal dialysis, intermittent peritoneal dialysis and kidney transplantation. Such treatments partially exert the renal function, alleviating disease symptoms and preserving the patient's life, without generating a cure. Chronic kidney patients use several drugs concomitantly, which, associated with changes in the glomerular filtration rate, multiple comorbidities and age, increase the risk of drug interactions. Objective: The aim of the present study is the pharmacotherapeutic follow-up of patients with chronic kidney disease, aiming at improving their quality of life in this population, which, due to the practice of polypharmacy and the presence of various diseases, usually has their quality of life reduced. Methods: Data present in the patient's medical record and the SOAP (Subjective, Objective, Assessment, Plan) allowed the collection and organization of patient data, the identification of problems related to pharmacotherapy, the elaboration of a care plan together with the patient and put an end to individual follow-up of the patient. Results: Of the 5 patients interviewed, in 1 there was no drug interaction, however, 4 had drug interactions, referring to their pharmacological treatment, totaling 12 interactions, with 6 (50%) severe interactions, 5 (41.67%) moderate and 1 (8 .33%) light. Conclusions: This research allowed to carry out pharmacotherapeutic monitoring in chronic kidney patients, who, due to their condition, have prescription restrictions of different therapeutic classes that can generate adverse effects in relation to renal function and age, resulting in polypharmacy and DRPs. Keywords: kidney disease, pharmacist, interactions. Expandir Resumo Acessar Texto Completo